Risk factors

Marker Therapeutics (MRKR) risk factors

Item 1A of every Marker Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open MRKR in Gloomberb →
  • FY2025 10-K risk factors

    49 risks, 3 new, 13 dropped, 8 reworded since the prior year. Marker now emphasizes outsourced manufacturing: no cGMP facility, BCM reliance, and Cellipont's MT-601 work ahead of a 2026 lymphoma trial.

    Filed Mar 18, 2026
  • FY2024 10-K risk factors

    59 risks. Clinical stage immunotherapy company with a history of continuous operating losses.

    Filed Mar 31, 2025